[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630734":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":10,"centralContacts":31,"locations":37,"responsibleParty":56,"collaborators":10,"id":60,"slug":10,"hasResults":61,"nctId":62,"briefTitle":63,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":61,"sex":65,"minAge":66,"maxAge":10,"enrollmentInfo":67,"targetDuration":10,"studyType":70,"phases":10,"briefSummary":71,"conditions":72,"keywords":10,"overallStatus":40,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"University of Patras","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Patient with ssc-ild with a double immunosuppression treatment and with anti fibrotic",null,"Comparison of the two groups",[13,14],"Drug: Antifibrotic drugs (nidanib or pirfenidone)","Drug: MMF Immunosuppression",{"label":16,"type":10,"description":17,"interventionNames":18},"Patient with ssc-ild with a double immunosuppression treatment only","Patients with rituximab and mmf",[14],[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":10},"DRUG","Antifibrotic drugs (nidanib or pirfenidone)","Ssc - ild",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":29},"MMF Immunosuppression","we will compare patients with SSc-ILD taking RTX and mmf and patients that are taking RTX,mmf and nintedanib",[9,16],[30],"RITUXIMAB",[32],{"name":33,"role":34,"phone":35,"phoneExt":10,"email":36},"Stamatis Nick Liossis C Professor, MD, PhD","CONTACT","+306977066105","snliossis@med.upatras.gr",[38],{"facility":39,"status":40,"city":41,"state":10,"zip":10,"country":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"University of patras","RECRUITING","Pátrai","Greece",{"type":44,"coordinates":45},"Point",[46,47],21.73508,38.2462,{"lat":47,"lon":46},[50,53],{"name":51,"role":34,"phone":52,"phoneExt":10,"email":36},"University of patraS SNL, PROF","+30 697 7066105",{"name":54,"role":55,"phone":10,"phoneExt":10,"email":10},"stephanie erotokritou, MD","SUB_INVESTIGATOR",{"type":57,"investigatorFullName":58,"investigatorTitle":59,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Liossis Stamatis Nick","Professor","100630734",false,"NCT07491523","Double Immunosuppression With or Without Anti-fibrotic in Scleroderma ILD","Inclusion Criteria:ild-ssc with double immunosuppression\n\n\\-\n\nExclusion Criteria:\n\n* ssc without ild","ALL","18 Years",{"count":68,"type":69},35,"ESTIMATED","OBSERVATIONAL","Patients with ssc-ild receiving double immunosuppression with or without anti fibrotic tratment",[73],"SSc-Systemic Sclerosis","2026-03-19",{"date":76,"type":77},"2026-03-24","ACTUAL",{"date":79,"type":77},"2025-06-01",{"date":81,"type":69},"2027-03",{"name":5,"class":6},1]